SINAPPS stands for Study of Immunology in Antibody Positive Psychosis. We are a research group formed of collaborating Universities in the UK, investigating the role of autoimmune antibodies as a cause of psychosis.
SINAPPS2 TRIAL MANAGEMENT GROUP
Find out more about our group members by clicking on their names.
Professor Alasdair Coles Chief Investigator and Principal Investigator, University of Cambridge
Professor Belinda Lennox Principal investigator, University of Oxford
Professor Eileen Joyce, Co-investigator, University College London
Dr Michael Zandi , Principal Investigator, UCL Hospitals NHS Trust, London
Dr Thomas Kabir, Head of Public Involvement,
Mr Francis Dowling, Senior Trial Coordinator, Cambridge Clinical Trial Unit
SINAPPS2 Trial PRINCIPAL Investigators
Dr Akram Hosseini, Queen's Medical Centre, Nottingham
Dr John Goodfellow, Queen Elizabeth University Hospital, Glasgow